PregLem
Established: 2006
Country: Switzerland
Region: Geneva
Investors: Sofinnova Investments, MVM Partners, NeoMed, Sofinnova Partners
PregLem was established with a focus on women’s reproductive health, including common conditions such as uterine fibroids (myoma), endometriosis and infertility.
Venture capital helped the Geneva-based start-up to hire key employees and establish licensing agreements with pharmaceutical groups Ipsen and HRA Pharma to develop and commercialise promising compounds1. PregLem was bought by Hungary’s largest drugmaker Gedeon Richter, a specialist in women’s reproductive health, in 2010 for CHF445 million, which included milestone payments of CHF295 million. Gedeon Richter pledged to invest a further CHF100 million in the company to help it develop its portfolio of drugs2.
ESMYA Long Term Treatment 2017 (Video – 02:53)
$68m
raised in VC funding
CHF445m
acquisition by Gedeon Richter
62
jobs created
Key achievements
Developing drugs for unmet medical needs in women’s reproductive health
Acquired by Gedeon Richter for CHF445m, including CHF295m in milestone payments
Funding history
Raised $68m in VC funding3
Employment impact
Created 62 jobs4
Find out more
1. https://neomed.net/portfolio/234.html
2. https://www.reuters.com/article/richter-preglem-idINLDE6960SB20101007
3. Preqin
4. Public sources
Investors
